154 related articles for article (PubMed ID: 18202801)
1. Immunostimulatory effect of Fms-like tyrosine kinase 3 ligand on peripheral monocyte-derived dendritic cells and natural killer cells: utilization for ovarian cancer treatment.
Matsumura N; Mandai M; Hamanishi J; Yamaguchi K; Fukuhara K; Yagi H; Higuchi T; Takakura K; Fujii S
Oncol Rep; 2008 Feb; 19(2):505-15. PubMed ID: 18202801
[TBL] [Abstract][Full Text] [Related]
2. Dendritic cells engineered to express the Flt3 ligand stimulate type I immune response, and induce enhanced cytoxic T and natural killer cell cytotoxicities and antitumor immunity.
Liu Y; Huang H; Chen Z; Zong L; Xiang J
J Gene Med; 2003 Aug; 5(8):668-80. PubMed ID: 12898636
[TBL] [Abstract][Full Text] [Related]
3. Cancer gene therapy using in vivo electroporation of Flt3-ligand.
Shimao K; Takayama T; Enomoto K; Saito T; Nagai S; Miyazaki J; Ogawa K; Tahara H
Int J Oncol; 2005 Aug; 27(2):457-63. PubMed ID: 16010428
[TBL] [Abstract][Full Text] [Related]
4. No defect in T-cell priming, secondary response, or tolerance induction in response to inhaled antigens in Fms-like tyrosine kinase 3 ligand-deficient mice.
Walzer T; Brawand P; Swart D; Tocker J; De Smedt T
J Allergy Clin Immunol; 2005 Jan; 115(1):192-9. PubMed ID: 15637568
[TBL] [Abstract][Full Text] [Related]
5. Flt3 ligand promotes myeloid dendritic cell differentiation of human hematopoietic progenitor cells: possible application for cancer immunotherapy.
Harada S; Kimura T; Fujiki H; Nakagawa H; Ueda Y; Itoh T; Yamagishi H; Sonoda Y
Int J Oncol; 2007 Jun; 30(6):1461-8. PubMed ID: 17487367
[TBL] [Abstract][Full Text] [Related]
6. Coexpression of Flt3 ligand and GM-CSF genes modulates immune responses induced by HER2/neu DNA vaccine.
Yo YT; Hsu KF; Shieh GS; Lo CW; Chang CC; Wu CL; Shiau AL
Cancer Gene Ther; 2007 Nov; 14(11):904-17. PubMed ID: 17704754
[TBL] [Abstract][Full Text] [Related]
7. Murine mammary adenocarcinoma cells transfected with p53 and/or Flt3L induce antitumor immune responses.
Sang H; Pisarev VM; Chavez J; Robinson S; Guo Y; Hatcher L; Munger C; Talmadge CB; Solheim JC; Singh RK; Talmadge JE
Cancer Gene Ther; 2005 Apr; 12(4):427-37. PubMed ID: 15678151
[TBL] [Abstract][Full Text] [Related]
8. Impact of the tumor microenvironment on host infiltrating cells and the efficacy of flt3-ligand combination immunotherapy evaluated in a treatment model of mouse prostate cancer.
Ciavarra RP; Brown RR; Holterman DA; Garrett M; Glass WF; Wright GL; Schellhammer PF; Somers KD
Cancer Immunol Immunother; 2003 Sep; 52(9):535-45. PubMed ID: 14627125
[TBL] [Abstract][Full Text] [Related]
9. FLT3 ligand administration after hematopoietic cell transplantation increases circulating dendritic cell precursors that can be activated by CpG oligodeoxynucleotides to enhance T-cell and natural killer cell function.
Chen W; Chan AS; Dawson AJ; Liang X; Blazar BR; Miller JS
Biol Blood Marrow Transplant; 2005 Jan; 11(1):23-34. PubMed ID: 15625541
[TBL] [Abstract][Full Text] [Related]
10. Immuno-gene therapy with adenoviruses expressing fms-like tyrosine kinase 3 ligand and CD40 ligand for mouse hepatoma cells in vivo.
Yanagi K; Nagayama Y; Nakao K; Saeki A; Matsumoto K; Ichikawa T; Ishikawa H; Hamasaki K; Ishii N; Eguchi K
Int J Oncol; 2003 Feb; 22(2):345-51. PubMed ID: 12527933
[TBL] [Abstract][Full Text] [Related]
11. Spleen but not tumor infiltration by dendritic and T cells is increased by intravenous adenovirus-Flt3 ligand injection.
Solheim JC; Reber AJ; Ashour AE; Robinson S; Futakuchi M; Kurz SG; Hood K; Fields RR; Shafer LR; Cornell D; Sutjipto S; Zurawski S; LaFace DM; Singh RK; Talmadge JE
Cancer Gene Ther; 2007 Apr; 14(4):364-71. PubMed ID: 17235356
[TBL] [Abstract][Full Text] [Related]
12. Treatment of hepatocellular carcinoma with adenoviral vector-mediated Flt3 ligand gene therapy.
Wang H; Dai J; Hou S; Qian W; Li B; Ma J; Fan X; Zhao J; Yang S; Sang H; Yang Q; Wang R; Guo Y
Cancer Gene Ther; 2005 Sep; 12(9):769-77. PubMed ID: 15877081
[TBL] [Abstract][Full Text] [Related]
13. Differential expansion of umbilical cord blood mononuclear cell-derived natural killer cells dependent on the dose of interleukin-15 with Flt3L.
Nagamura-Inoue T; Mori Y; Yizhou Z; Watanabe N; Takahashi TA
Exp Hematol; 2004 Feb; 32(2):202-9. PubMed ID: 15102482
[TBL] [Abstract][Full Text] [Related]
14. A novel approach to induce human DCs from monocytes by triggering 4-1BBL reverse signaling.
Ju S; Ju S; Ge Y; Qiu H; Lu B; Qiu Y; Fu J; Liu G; Wang Q; Hu Y; Shu Y; Zhang X
Int Immunol; 2009 Oct; 21(10):1135-44. PubMed ID: 19684160
[TBL] [Abstract][Full Text] [Related]
15. Pilot study of Flt3 ligand comparing intraperitoneal with subcutaneous routes on hematologic and immunologic responses in patients with peritoneal carcinomatosis and mesotheliomas.
Freedman RS; Vadhan-Raj S; Butts C; Savary C; Melichar B; Verschraegen C; Kavanagh JJ; Hicks ME; Levy LB; Folloder JK; Garcia ME
Clin Cancer Res; 2003 Nov; 9(14):5228-37. PubMed ID: 14614003
[TBL] [Abstract][Full Text] [Related]
16. TLR8-driven IL-12-dependent reciprocal and synergistic activation of NK cells and monocytes by immunostimulatory RNA.
Berger M; Ablasser A; Kim S; Bekeredjian-Ding I; Giese T; Endres S; Hornung V; Hartmann G
J Immunother; 2009 Apr; 32(3):262-71. PubMed ID: 19242374
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of dysregulation of the receptor tyrosine kinases Kit, Flt3, and Met in histiocytic sarcomas of dogs.
Zavodovskaya R; Liao AT; Jones CL; Yip B; Chien MB; Moore PF; London CA
Am J Vet Res; 2006 Apr; 67(4):633-41. PubMed ID: 16579756
[TBL] [Abstract][Full Text] [Related]
18. Dendritic cell homeostasis is maintained by nonhematopoietic and T-cell-produced Flt3-ligand in steady state and during immune responses.
Saito Y; Boddupalli CS; Borsotti C; Manz MG
Eur J Immunol; 2013 Jun; 43(6):1651-8. PubMed ID: 23519969
[TBL] [Abstract][Full Text] [Related]
19. Delivery of Flt3 ligand (Flt3L) using a poloxamer-based formulation increases biological activity in mice.
Robinson SN; Chavez JM; Pisarev VM; Mosley RL; Rosenthal GJ; Blonder JM; Talmadge JE
Bone Marrow Transplant; 2003 Mar; 31(5):361-9. PubMed ID: 12634727
[TBL] [Abstract][Full Text] [Related]
20. Characterization of monocyte-derived IFNalpha-generated dendritic cells.
Jacobs B; Wuttke M; Papewalis C; Fenk R; Stüssgen C; Baehring T; Schinner S; Raffel A; Seissler J; Schott M
Horm Metab Res; 2008 Feb; 40(2):117-21. PubMed ID: 18283629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]